FMC Corporation

FMC Corporation (FMC) Market Cap

FMC Corporation has a market capitalization of $2.15B.

Financials based on reported quarter end 2025-12-31

Price: $17.17

-0.41 (-2.33%)

Market Cap: 2.15B

NYSE · time unavailable

CEO: Pierre R. Brondeau

Sector: Basic Materials

Industry: Agricultural Inputs

IPO Date: 1980-03-17

Website: https://www.fmc.com

FMC Corporation (FMC) - Company Information

Market Cap: 2.15B · Sector: Basic Materials

FMC Corporation, an agricultural sciences company, provides crop protection, plant health, and professional pest and turf management products. It develops, markets, and sells crop protection chemicals that include insecticides, herbicides, and fungicides; and biologicals, crop nutrition, and seed treatment products, which are used in agriculture to enhance crop yield and quality by controlling a range of insects, weeds, and diseases, as well as in non-agricultural markets for pest control. The company markets its products through its own sales organization and through alliance partners, independent distributors, and sales representatives. It operates in North America, Latin America, Europe, the Middle East, Africa, and Asia. FMC Corporation was founded in 1883 and is headquartered in Philadelphia, Pennsylvania.

Analyst Sentiment

57%
Buy

Based on 18 ratings

Analyst 1Y Forecast: $21.82

Average target (based on 5 sources)

Consensus Price Target

Low

$13

Median

$14

High

$43

Average

$19

Potential Upside: 11.1%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 FMC CORP (FMC) — Investment Overview

🧩 Business Model Overview

FMC Corporation operates as a global specialty agricultural sciences company, with a core focus on the development, manufacture, and commercialization of crop protection solutions. The company’s primary value proposition centers around providing farmers with innovative chemistries and biologicals that enhance yield, protect crops from pests, fungi, and weeds, and ultimately improve agricultural productivity. FMC’s operations span discovery research, formulation, and distribution, integrating vertically to maintain control over intellectual property, regulatory approvals, and commercialization strategies. The company’s strategy emphasizes product innovation, research and development (R&D) leadership, and geographic diversification.

💰 Revenue Streams & Monetisation Model

The primary revenue stream for FMC is the sale of crop protection products, including insecticides, herbicides, and fungicides. These products are sold to a diverse customer base that includes agricultural distributors, retailers, co-operatives, and directly to large farming operations. FMC monetizes its research pipeline by launching new active ingredients and product formulations that command pricing premiums and longer duration of market exclusivity. Supplemental revenues are derived from licensing proprietary technologies, providing contract research services, and selectively partnering with other agrochemical firms for co-distribution or development programs. The company’s global footprint ensures that revenues are distributed across key agricultural markets in North America, Latin America, Asia-Pacific, and EMEA, insulating against regional volatility and harvest cycles.

🧠 Competitive Advantages & Market Positioning

FMC holds a strong competitive position within the crop protection industry by leveraging a differentiated research pipeline, an extensive patent portfolio, and a well-established global distribution network. The company’s focus on proprietary active ingredients, particularly in insecticides and herbicides, supports its ability to command favorable pricing and maintain customer loyalty. Legacy investments in R&D have yielded a robust pipeline of next-generation products, including advanced synthetic chemistries and biologically derived solutions. FMC distinguishes itself further through regulatory expertise, enabling faster time-to-market for innovations in complex regulatory environments. Strategic acquisitions and targeted geographic expansion have bolstered its product portfolio and access to growth markets. While larger competitors may have greater scale, FMC’s agility and targeted innovation often enable faster response to industry shifts and agronomic trends.

🚀 Multi-Year Growth Drivers

FMC’s growth is driven by a confluence of secular and company-specific factors. Rising global demand for food, feed, and fiber sustains the need for crop protection products that optimize agricultural yields. Population growth and limited arable land intensify pressures to maximize productivity per acre, necessitating continued innovation in plant protection. FMC’s investments in R&D are expected to yield a pipeline of proprietary chemistries and biologicals, supporting ongoing product launches and share gains. The company’s expansion in developing markets—especially in regions where mechanization and crop protection adoption are increasing—offers opportunity for volumetric growth. Adoption of sustainable agriculture practices also positions FMC’s biological and low-residue solutions for expanded market acceptance. Strategic partnerships, licensing of intellectual property, and selective M&A further support long-term accretion to the top and bottom lines.

⚠ Risk Factors to Monitor

FMC operates in a sector characterized by significant regulatory oversight, cyclicality, and competitive intensity. Regulatory risk is material, as crop protection products require extensive registration and compliance, with evolving environmental standards posing the risk of product bans or market withdrawals. The pipeline depends on successful R&D outcomes, which are inherently uncertain and capital-intensive. The industry faces pricing pressure from both generic competition and global agrochemical giants. Volatility in commodity prices, foreign exchange, and weather patterns can impact farmer purchasing decisions and overall demand. ESG considerations around chemical usage and environmental impact may further influence policy, customer preferences, and potential litigation. Geopolitical tensions and trade barriers also present risks to global operations and supply chains.

📊 Valuation & Market View

FMC’s valuation is frequently benchmarked against both specialty chemical firms and agricultural input peers. The company’s multiples often reflect a premium attributable to its high-margin proprietary products, innovation pipeline, and global presence, while also embedding risks tied to its exposure to cyclical end markets and regulatory headwinds. The investment community generally views FMC as a differentiated mid-cap player balancing defensive agricultural end-market dynamics with growth from pipeline launches and emerging markets penetration. Capital return policies—including dividends and selective share repurchases—provide additional support to shareholder value, while prudent leverage and strong cash generation underpin financial stability. Nonetheless, earnings and valuation are sensitive to factors such as product mix shifts, regulatory events, and agricultural cycle developments.

🔍 Investment Takeaway

FMC Corporation represents an established and innovative pure-play in the global crop protection industry, offering leveraged exposure to secular agricultural demand trends, a robust R&D engine, and a diverse product and geographic mix. Its competitive advantages are anchored in a strong patent portfolio, deep customer relationships, and a track record of pipeline execution. While regulatory, operational, and market risks are non-trivial, FMC’s positioning and growth prospects suggest potential for attractive, long-term risk-adjusted returns, especially for investors seeking diversified exposure to agribusiness innovation.

⚠ AI-generated — informational only. Validate using filings before investing.

Management presents a “double path” story: a base plan to strengthen the balance sheet (over $1B debt reduction) and stabilize the portfolio, running in parallel with a full-company strategic review. Prepared remarks are confident on the growth engine (four new actives; mid-teens EBITDA growth targeted for 2027–2028) but acknowledge the dominant 2026 drag is the legacy non-Rynaxypyr core—explicitly described as not cost-competitive manufacturing (about $1B of production) and challenged by generics, including Latin America. Q&A pressure centered on how the $700M EBITDA target is achievable and whether volatility can be controlled; management’s answer was that product-line profitability isn’t broken out, and that the only big unresolved items are (1) core manufacturing competitiveness and (2) the Rynaxypyr diamide partner pricing/volume constraints. Actual execution risks are concentrated in 1Q: EBITDA margin guided ~7% due to tariffs ($20M, nearly all in Q1) and early manufacturing cost headwinds, plus partner/genetic adoption effects.

AI IconGrowth Catalysts

  • Four new active ingredients (new AIs) sales growing: ~$130M (2024) to ~$200M (2025); led by fluindapyr and isoflex
  • Fluindapyr fungicide: registered/launched in major countries (including US and Brazil); expanding via grower education; full 2026 selling season in Great Britain after delayed 2025 registration
  • Isoflex: “accelerating growth” with full selling season in Great Britain in 2026
  • IDLECs active herbicide (first new mode of action in 30+ years); expect “meaningful contribution from Godelix beginning in 2027”
  • Rimisoxafen registration expected to begin in 2028
  • Renisuxaffin: dual mode of action herbicide targeted to Palmer Amaranth resistant to 8 herbicide classes

Business Development

  • India commercial business sale process underway; board/management said formal strategic review does NOT affect India sale; “binding bids expected… in the second quarter”
  • Licensing agreements including upfront payments (upfront payment referenced broadly; no named counterpart provided)
  • Rynaxypyr strategy includes cost-plus pricing contract mechanism with diamide partners (partner sales expected lower due to cost, price, and volume)

AI IconFinancial Highlights

  • Q4 2025 sales: $1.08B; -11% YoY (-5% like-for-like excluding India)
  • Q4 2025 adjusted EBITDA: $280M; -17% YoY (-8% like-for-like excluding India)
  • Q4 price: -6% YoY (lower Rynaxypyr + strong competition, especially Latin America)
  • Q4 volume: -1% YoY (weaker than anticipated; driven by competitive pressure)
  • Q4 adjusted EPS: $1.20; -33% (lower adjusted EBITDA + higher interest)
  • Q4 GAAP cash from operations: $657M; free cash flow (FCF): $623M (working capital release; particularly receivables)
  • FY 2025 cash flow: cash from operations negative $6M; FY 2025 FCF negative $165M (includes $103M cash restructuring spend)
  • 2026 guidance: full-year sales $3.6B–$3.8B (-5% at midpoint vs prior year); price mid-single-digit headwind
  • 2026 guidance: full-year adjusted EBITDA $670M–$730M (management cited ~ $700M target in Q&A)
  • 2026 guidance: India removal expected ~2% full-year headwind, impacting only first half
  • 1Q 2026 guidance: sales $725M–$775M (5% lower than prior year); EBITDA margin ~7% due to abnormally low margin profile (Q1-only)
  • Tariffs: expected $20M headwind, “nearly all” impacting first-quarter results; recorded almost entirely in Q1
  • 2026 free cash flow: -$65M to +$65M (breakeven at midpoint) including expected $130M restructuring spending
  • 2026 leverage: reduction in net leverage of ~one-half turn expected after debt paydown plan; covenant limit 6.0x through 2026, stepping down to 5.5x at year-end

AI IconCapital Funding

  • Debt paydown target: pay down over $1B of debt via asset sales and licensing agreements (explicitly linked to India sale plus licensing upfront payments)
  • Net debt: ~$3.5B at Q4 2025, down >$550M vs Q3 due to strong free cash flow
  • Covenant leverage: 4.6x at year-end 2025; trailing twelve-month net debt/EBITDA 4.1x
  • Expected 2026 FCF range supports liquidity through a breakeven midpoint; includes $130M restructuring spending

AI IconStrategy & Ops

  • Core off-patent (non-diamide) manufacturing competitiveness: expect to lower manufacturing cost by at least 35% by 2027; requires re-registration for most products and inventory buildup ahead of transitions
  • Operational constraint: limited ability to adapt manufacturing mix to changing customer needs; management expects this reduced flexibility to be a sales headwind in 2026
  • Rynaxypyr cost strategy constrained by partner contracts: management described nearing a “limit” to further cost decreases for Rynaxypyr partner pricing and expects the impact to become “very minor” in 2027
  • Q1 2026 cost headwinds: unfavorable manufacturing costs early in the year and unique Q1 cost factors; margin profile expected to normalize in subsequent quarters

AI IconMarket Outlook

  • 2026 full-year sales: $3.6B–$3.8B; adjusted EBITDA $670M–$730M
  • 2026 first-quarter sales: $725M–$775M
  • 2026 new active ingredients sales: $300M–$400M
  • Expectation: branded Rynaxypyr earnings in 2026 to be “in line” with prior year (flat earnings)
  • Expectation: EBITDA growth in mid-teens % in both 2027 and 2028 (per prepared remarks)
  • India sale: binding bids expected in Q2 (timeline explicitly stated)

AI IconRisks & Headwinds

  • Legacy/core portfolio competitiveness pressure: core products (excluding Rynaxypyr) are the main challenge; management referenced ~$1B of production in non-cost-competitive high-cost manufacturing and acknowledged losing market share; shrinking on this part described as ~34% (as stated in Q&A)
  • Generic CTPR/renamed CTPR offerings: “a large number of generic CTPR offerings” announced in US and Brazil after patent expiry; distributors/retailers reluctant to fully stock until quality/availability/grower response is understood; management expects lower diamide partner orders in 1Q
  • Partner sales headwind: Rynaxypyr partner contract faces lower orders due to reduced volumes and partner pricing cost adjustments via cost-plus mechanism
  • Planned registration losses in Europe: impacts volume growth
  • Tax/tariff: tariffs expected to be a $20M headwind, nearly entirely in Q1; also described as recorded almost entirely in Q1
  • Macroe/industry: weaker grower margins and intense generics competition driving timing of purchases and product mix (management cited in Q4 commentary)
  • Resistance dynamics: pest resistance in rice crops in China and Japan increases, with impact requiring advanced formulations/mixtures (mitigation described via formulation strategy)

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the FMC Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"FMC reported revenues of $1.136 billion for the quarter ending December 31, 2025. However, the company posted a significant net loss of $1.7208 billion, translating to an EPS of -$13.77. The net margin was severely negative. Free cash flow was -$107.9 million, indicating cash constraints, with negative operating cash flow of -$154.5 million. Year-over-year growth has been challenged. The balance sheet reflects total assets of $9.6872 billion, and net debt stands at $720.6 million with no liabilities or equity reported, indicating potential restructuring or financial complexity. The absence of buybacks and continuous dividend payments, albeit reduced, might strain cash reserves. Analyst consensus suggests a cautious outlook with price targets ranging from $13 to $43, underscoring market uncertainty. Valuation and sentiment seem pressured by operational challenges."

Revenue Growth

Neutral

Revenue growth appears stagnant, with performance challenged by broader industry factors and internal issues.

Profitability

Neutral

Profitability is severely impacted by substantial net losses, reflecting inefficiencies or one-time charges.

Cash Flow Quality

Neutral

Cash flow is negative, both in operating and free cash flow, indicating potential liquidity bottlenecks and constrained financial flexibility.

Leverage & Balance Sheet

Caution

Net debt is relatively moderate against significant asset base, yet the balance sheet shows complexities with absent equity and liabilities reporting.

Shareholder Returns

Neutral

Dividend payments are ongoing but reduced, presenting limited return prospects given the lack of stock buybacks or strategic reinvestments.

Analyst Sentiment & Valuation

Fair

Analyst sentiment reflects uncertainty with wide-ranging price targets, suggesting cautious investor outlook amidst aggressive strategic realignments.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
📁

SEC Filings (FMC)

© 2026 Stock Market Info — FMC Corporation (FMC) Financial Profile